Japanese journal of clinical oncology最新文献

{"title":"Prognostic factors and overall survival for recurrent and metastatic head and neck squamous cell carcinoma: a multicenter retrospective analysis.","authors":"Kazufumi Obata, Satoshi Kano, Akira Ohkoshi, Akito Kakiuchi, Takahiro Inoue, Jun Taguchi, Ai Tagawa, Daisuke Matsushita, Jun Miyaguchi, Tentaro Endo, Ryo Ishii, Kazue Ito, Eiichi Ishida, Takahiro Suzuki, Naoto Araki, Tomotaka Kawase, Kenichi Takano","doi":"10.1093/jjco/hyaf088","DOIUrl":"10.1093/jjco/hyaf088","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors (ICIs) improve outcomes in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). However, some patients remain unresponsive to treatment, necessitating further investigation into optimal therapeutic strategies and prognostic biomarkers. This study aimed to evaluate the efficacy of various therapies and identify factors influencing overall survival (OS) in these patients.</p><p><strong>Methods: </strong>We retrospectively analyzed 606 patients (517 men, 89 women; median age 68 years) treated at 13 head and neck cancer specialty facilities in Japan between January 2018 and December 2022. Associations between OS and variables, including age, sex, primary site, Eastern Cooperative Oncology Group performance status, estimated glomerular filtration rate, therapeutic target lesion, history of drug use in systemic chemotherapy, number of treatment lines, nondrug treatments, de novo metastasis, programmed death-ligand 1 combined positive score, and platinum resistance were statistically examined.</p><p><strong>Results: </strong>Median OS was 14.2 months, and median progression-free survival was 5.0 months. Multivariate analysis identified poor OS in patients with oral cavity tumors and performance status 2-3, whereas ICI therapy and nondrug salvage interventions were associated with improved OS. ICI/non-ICI subgroup analysis revealed that ICI may have a limited effect on oral cancer. Additionally, our results indicated that a history of platinum therapy for R/M HNSCC may not affect the therapeutic efficacy of ICIs.</p><p><strong>Conclusion: </strong>For patients with R/M HNSCC, further OS improvement may be achieved using ICIs or aggressive nondrug salvage therapy and by considering the use of chemotherapy other than ICI for patients with oral cancer or poor PS.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1013-1021"},"PeriodicalIF":2.2,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144159078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age-standardized mortality-to-incidence ratio for cervical and corpus uteri cancer in the world.","authors":"Kayo Nakata, Hadrien Charvat","doi":"10.1093/jjco/hyaf132","DOIUrl":"https://doi.org/10.1093/jjco/hyaf132","url":null,"abstract":"","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":"55 9","pages":"1093-1094"},"PeriodicalIF":2.2,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145000496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Narrative review of cancer bereavement care before loss.","authors":"Emi Takeuchi, Ryoichi Sadahiro, Yuko Ogawa, Hiromichi Matsuoka","doi":"10.1093/jjco/hyaf085","DOIUrl":"10.1093/jjco/hyaf085","url":null,"abstract":"<p><p>Contrary to sudden death, cancer death allows families to have a certain period to be ready for death and receive some support from health care providers. This review aims to picture a family's experience of cancer trajectory that is associated with bereavement outcomes and health care provider's care provided before loss. We reviewed pre-loss factors associated with grief and indicated that preparedness for death may contribute to alleviating grief. Simultaneously, families are afraid of confronting bereavement and under pressure to prepare for death by making decisions about death-related treatments and providing caregiving. Throughout our review of randomized control trials of pre-loss interventions, we found almost no interventions that improve preparedness for death. Some guidelines and literature demonstrate that communication is the key to promoting preparedness properly. Early discussion to provide information and opportunity for decision-making regarding preparing for death is desired, as well as being aware of families' feelings of resistance to engaging in discussion and losing hope in prolonging the patient's life. Through communication, oncologists can support them, creating a soft landing toward the stages of loss. This process of preparing for loss ultimately may contribute to grief care.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"985-990"},"PeriodicalIF":2.2,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The pattern of lymph node metastasis in patients with peripheral non-small cell lung cancer >2-3 cm.","authors":"Tomohiro Maniwa, Hisaya Chikaraishi, Hironobu Samejima, Masao Kobayashi, Julian Horiguchi, Ryu Kanzaki, Jiro Okami","doi":"10.1093/jjco/hyaf097","DOIUrl":"10.1093/jjco/hyaf097","url":null,"abstract":"<p><strong>Background: </strong>Several studies have reported the pattern of lymph node (LN) metastasis in patients undergoing segmentectomy for non-small cell lung cancer (NSCLC) <2 cm. However, the pattern of LN metastasis in cases of NSCLC >2-3 cm remains unknown.</p><p><strong>Methods: </strong>This retrospective study reviewed the clinicopathological features of 406 consecutive patients with NSCLC (≤3 cm, cN0) who underwent segmentectomy or lobectomy between January 2017 and December 2023. The tumours were classified into part-solid tumours ≤2 cm (Group A, n = 80), pure-solid tumours ≤2 cm (Group B, n = 72), part-solid tumours >2-3 cm (Group C, n = 140), and pure-solid tumours >2-3 cm (Group D, n = 113). Patterns of LN metastasis, recurrence, and pathological invasive factors were compared amongst the four groups.</p><p><strong>Results: </strong>The number of patients with pN1/pN2a/pN2b in Groups A, B, C, and D were 0/1/0, 4/0/0, 5/6/1, and 9/2/3, respectively. There was no difference in the pathological invasive factors between Groups A and B. No patient with part-solid tumours had non-adjacent interlobar LN metastasis or hilar or mediastinal LN recurrence. Group D (37.2%) had more lymphatic invasion than Group C (25.0%) (P = 0.040). One patient with a pure-solid tumour had non-adjacent interlobar LN metastasis. None of the patients with part-solid tumours in the upper lobe experienced recurrence outside the region of selective LN dissection.</p><p><strong>Conclusion: </strong>Non-adjacent interlobar or mediastinal lymph node dissection may be omitted for pure-solid tumours even if indicated segmentectomy for NSCLC >2-3 cm. Selective LN dissection is adequate for patients with pure-solid upper lobe tumours >2-3 cm.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1073-1079"},"PeriodicalIF":2.2,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hormone replacement therapy in female-specific cancer survivors: considerations beyond cancer cure.","authors":"Tomoko Yoshihama, Megumi Yokota, Daisuke Aoki, Wataru Yamagami","doi":"10.1093/jjco/hyaf092","DOIUrl":"10.1093/jjco/hyaf092","url":null,"abstract":"<p><p>With rapid advances in disease diagnosis and treatment, patients with cancer will achieve longer survival. Among female cancer survivors, oncologic treatments often lead to premature ovarian insufficiency, negatively impacting their health and quality of life. Hormone replacement therapy (HRT) may mitigate these effects; however, concerns remain regarding its impact on oncologic outcomes. Updating the evidence base could help healthcare providers identify patients who may benefit from HRT without an increased risk of recurrence. This review provides an updated overview of HRT in women with a history of cervical, endometrial, ovarian, and breast cancers. For cervical cancer, HRT is not contraindicated in either squamous cell carcinoma or adenocarcinoma, regardless of stage. For endometrial cancer, HRT is not contraindicated in early-stage disease with no residual tumor, although it should be avoided in low-grade endometrial stromal sarcoma. HRT is not contraindicated in epithelial ovarian cancer regardless of stage, except in low-grade serous carcinoma. Currently, HRT is contraindicated for breast cancer. This review highlights the need to promote long-term healthcare strategies for cancer survivors. A shift in focus beyond cancer cure toward lifelong health management is warranted.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1000-1004"},"PeriodicalIF":2.2,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12529068/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144208549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term real-world outcomes of nivolumab plus ipilimumab for advanced renal cell carcinoma: a minimum of 4-years follow-up study.","authors":"Hiroki Ishihara, Koichi Nishimura, Yuki Nemoto, Shinsuke Mizoguchi, Takayuki Nakayama, Hironori Fukuda, Hiroaki Shimmura, Yasunobu Hashimoto, Kazuhiko Yoshida, Junpei Iizuka, Kenji Omae, Tsunenori Kondo, Toshio Takagi","doi":"10.1093/jjco/hyaf093","DOIUrl":"10.1093/jjco/hyaf093","url":null,"abstract":"<p><strong>Background: </strong>Data regarding long-term outcomes of nivolumab plus ipilimumab for previously untreated advanced renal cell carcinoma (RCC) in real-world patients are limited.</p><p><strong>Methods: </strong>This retrospective study evaluated clinical data of 66 patients who received nivolumab plus ipilimumab with a minimum 4-years follow-up. Effectiveness and prognosis following deferred cytoreductive nephrectomy (CN) and treatment-free interval (TFI), as well as safety profiles, were assessed.</p><p><strong>Results: </strong>During the follow-up (median 39.7 months), 54 (82%) and 29 (44%) patients had disease progression and died, respectively. Median progression-free survival and overall survival (OS) were 8.98 and 62.1 months, respectively. Objective response was observed in 32 patients (48%), and the median duration of response was 21.1 months. Deferred CN was conducted in seven patients (11%), and the 3-year OS rate after deferred CN was 86%. TFI for at least 6 months was obtained in 13 patients (20%), with a 3-year OS rate after treatment-off was 92%. Grade ≥ 3 adverse events occurred in 29 patients (44%), and 11 patients (17%) required high-dose glucocorticoids (≥40 mg of prednisone/day).</p><p><strong>Conclusion: </strong>Long-term follow-up data showed a feasible effectiveness and safety profile of nivolumab plus ipilimumab for real-world patients with advanced RCC. Although prognosis following deferred CN and TFI appeared favorable, prospective randomized trials are needed to confirm survival benefit of deferred CN and TFI.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1080-1085"},"PeriodicalIF":2.2,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and age- and site-specific characteristics of osteosarcoma: a population-based study using National Cancer Registry 2016-2019.","authors":"Koichi Ogura, Chigusa Morizane, Tomoyuki Satake, Shintaro Iwata, Yu Toda, Shudai Muramatsu, Toshiyuki Takemori, Hiroya Kondo, Eisuke Kobayashi, Ayumu Arakawa, Chitose Ogawa, Yoko Katoh, Takahiro Higashi, Akira Kawai","doi":"10.1093/jjco/hyaf086","DOIUrl":"10.1093/jjco/hyaf086","url":null,"abstract":"<p><strong>Background: </strong>No previous reports have characterized national profiles of osteosarcoma. In this study, we examined nationwide statistics for osteosarcoma in Japan using data from the National Cancer Registry (NCR), a population-based cancer registry launched in 2016.</p><p><strong>Methods: </strong>We identified 1187 patients with osteosarcomas entered in the NCR during 2016-2019 using the cancer topography and morphology codes from the International Classification of Diseases for Oncology, Third Edition. We extracted data on patient demographics (sex, age), tumor details (reason for diagnosis, tumor location, extent of disease), hospital volume and facility type, treatment, and prognosis for each patient.</p><p><strong>Results: </strong>Osteosarcoma showed a slight male preponderance. Although osteosarcoma associated with Paget's disease of bone was extremely rare (0.2%), the age distribution had two peaks: in the second and the seventh to eighth decades of life, suggesting the bimodal age peaks in Japan result from the increasing proportion of the elderly population. Elderly osteosarcoma cases more commonly involved the axial skeleton including the craniofacial bones, pelvis, and spine and showed a lower frequency of localized disease at presentation. Furthermore, elderly patients were less likely to undergo intensive treatment involving chemotherapy and surgery, possibly leading to poorer survival outcomes associated with advanced age.</p><p><strong>Conclusions: </strong>This is the first study to analyze NCR data and provides an overview of the epidemiology, clinical features, treatment, prognosis, and significant factors affecting prognosis of patients with osteosarcoma in Japan. We must document our data regarding elderly patients' outcomes so other countries showing similar population aging trends can learn from our experiences.</p><p><strong>Level of evidence: </strong>Prognostic studies, Level III.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1037-1045"},"PeriodicalIF":2.2,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144208550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Transitional dynamics in oncology clinical trials: evaluating the impact of Clinical Trials Act on cooperative groups.","authors":"","doi":"10.1093/jjco/hyaf129","DOIUrl":"10.1093/jjco/hyaf129","url":null,"abstract":"","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1095"},"PeriodicalIF":2.2,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12411903/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144730979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic errors in subcutaneous myxofibrosarcoma: a retrospective case series before referral to specialist in bone and soft tissue tumors.","authors":"Kumiko Yotsuya, Yoji Shido, Yukihiro Matsuyama","doi":"10.1093/jjco/hyaf084","DOIUrl":"10.1093/jjco/hyaf084","url":null,"abstract":"<p><strong>Background: </strong>Malignant subcutaneous soft tissue sarcomas, including myxofibrosarcoma, are often misdiagnosed as benign soft tissue tumors by non-specialists. This study investigated the clinical features of subcutaneous myxofibrosarcoma before referral to our department specializing in bone and soft tissue tumors.</p><p><strong>Methods: </strong>A retrospective case series analysis was conducted on 26 patients with subcutaneous myxofibrosarcoma who were referred to our department between 2013 and 2024.</p><p><strong>Results: </strong>Of the 26 cases of subcutaneous myxofibrosarcoma referred to our department, 15 cases (57.7%) had \"diagnostic errors before referral,\" including seven cases of referral delay of ˃6 months, three cases of tumor puncture performed without suspicion of a tumor, four cases of unplanned biopsy, and seven cases of unplanned excision. The average time from the patient's first visit at a medical institution to the referral to our department was 22.7 ± 40.4 months (median 5.0 months, range 1-148 months). We performed initial wide resection in seven patients, additional wide resection in four patients, wide resection for recurrence in two patients, and amputation in two patients.</p><p><strong>Conclusions: </strong>Subcutaneous myxofibrosarcomas are rare; however, physicians who treat subcutaneous tumors need to be knowledgeable about them. This case series suggest that poorly planned biopsies may miss malignant tumors, and that careless puncturing may lead to deep invasion of the tumor. It also suggests that if you suspect a benign tumor, you should follow up with imaging, otherwise there is a possibility that it will lead to a significant delay in diagnosis.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1029-1036"},"PeriodicalIF":2.2,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Structure, availability, and organizational challenges of outpatient palliative care programmes in Japan: a nationwide survey.","authors":"Yoko Nakazawa, Risa Yamazaki, Nobuyuki Yotani, Yoshiyuki Kizawa","doi":"10.1093/jjco/hyaf095","DOIUrl":"10.1093/jjco/hyaf095","url":null,"abstract":"<p><strong>Background: </strong>Despite the growing recognition of outpatient palliative care (OPC), the organizational structure and service availability of OPC programmes in Japan remain insufficiently characterized. This study evaluates the structure, availability, and organizational challenges of hospital-based OPC programmes across Japan, comparing community hospitals (CHs) with designated cancer hospitals (DCHs).</p><p><strong>Methods: </strong>A nationwide cross-sectional survey, conducted in July 2022, targeted 624 hospitals, including those with registered palliative care teams from the Japanese Society of Palliative Medicine and DCHs. Programme leaders responded to a web-based questionnaire that included items on programme structure, service availability, and perceived organizational challenges. Logistic regression analysis was used to identify differences between CHs and DCHs.</p><p><strong>Results: </strong>Among the 338 responding hospitals (response rate: 54.2%), 302 reported active OPC programmes. Only 35.5% provided OPC services 5 days weekly, and 16.0% offered limited care exclusively for in-hospital patients. Monthly OPC visits were significantly lower at CHs (mean: 34.3) than at DCHs (mean: 69.6). Underdeveloped services included psychological follow-ups (CHs: 27.9%; DCHs: 45.1%) and a consultation system for regional providers (CHs: 55.8%; DCHs: 64.6%). Human resource shortages were widely perceived, particularly among palliative care nurses (CHs: 67.4%; DCHs: 78.2%) and psychiatrists (CHs: 53.5%; DCHs: 60.4%). Notably, CHs experienced significantly higher odds of encountering limited (OR: 3.12, 95% CI: 1.59-6.45) and delayed (OR: 2.24, 95% CI: 1.17-4.35) specialist referrals.</p><p><strong>Conclusions: </strong>OPC in Japan remains inadequately developed, with significant disparities between hospital types. Addressing critical human resource shortages and improving referral mechanisms through targeted policy interventions are essential to enhance OPC nationwide.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1062-1072"},"PeriodicalIF":2.2,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}